Adoption of resolutions at the Inventiva General Meeting

On June 30, 2026, Inventiva, a biopharmaceutical company listed in Paris and New York, held its Combined General Meeting in Paris. Under the chairmanship of Mr. Andrew Obenshain, most of the resolutions were adopted. However, the 31st resolution, which aimed to authorize the Board of Directors to proceed with reserved capital increases, was rejected following a negative recommendation from the Board.

The Assembly approved the remuneration policy for corporate officers, in accordance with the Universal Registration Document 2025. A notable participation with 71.874% of shares voting marked the meeting.

This meeting reflects the general approval of the company's direction by the shareholders while demonstrating vigilance on certain specific issues.